Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea.

OBJECTIVE: Obstructive sleep apnoea (OSA) is a relatively common condition producing disabling somnolence and profound physiological responses to hypoxaemic episodes during sleep, including significant oscillations in blood pressure. This study aimed to provide controlled data on the interaction bet...

Full description

Bibliographic Details
Main Authors: Meston, N, Davies, R, Mullins, R, Jenkinson, C, Wass, J, Stradling, JR
Format: Journal article
Language:English
Published: 2003
_version_ 1826273654618456064
author Meston, N
Davies, R
Mullins, R
Jenkinson, C
Wass, J
Stradling, JR
author_facet Meston, N
Davies, R
Mullins, R
Jenkinson, C
Wass, J
Stradling, JR
author_sort Meston, N
collection OXFORD
description OBJECTIVE: Obstructive sleep apnoea (OSA) is a relatively common condition producing disabling somnolence and profound physiological responses to hypoxaemic episodes during sleep, including significant oscillations in blood pressure. This study aimed to provide controlled data on the interaction between OSA and endocrine axes to establish whether overrepresentation of pathology such as hypertension and hypogonadism in OSA subjects might have an endocrine basis. DESIGN, SETTING AND SUBJECTS: Parallel randomized sham placebo controlled 1-month trial of nasal continuous positive airway pressure (nCPAP) in 101 male subjects with OSA presenting to a respiratory sleep clinic. METHODS: Analysis of gonadotrophins, testosterone, sex hormone binding protein (SHBG), prolactin, cortisol, thyroid stimulating hormone (TSH), free thyroxine (free T4), insulin-like growth factor-1 (IGF-1), renin and aldosterone were performed at baseline and after 1 month's active or placebo nCPAP intervention. Quality of life questionnaire scoring was also recorded over the same time period. RESULTS: Testosterone and SHBG showed significant negative correlations with baseline OSA severity. Active treatment of OSA produced SHBG elevation and TSH reduction (P< or =0.03). Both groups showed an increase in aldosterone (P<0.001) and IGF-1 (P< or =0.03), associated with a large improvement in subjective quality of life scoring. CONCLUSIONS: These findings demonstrate significant changes in endocrine axes not previously reported in a placebo-controlled trial. OSA is a recognized reversible cause of testosterone reduction; SHBG suppression correlating to baseline OSA severity supports a diagnosis of secondary hypogonadism. Significant rises in aldosterone and IGF-1 on treatment coincide with increased physical activity and an improved quality of life score.
first_indexed 2024-03-06T22:31:29Z
format Journal article
id oxford-uuid:58708ec8-8550-406c-bc1b-2be571bb3a1c
institution University of Oxford
language English
last_indexed 2024-03-06T22:31:29Z
publishDate 2003
record_format dspace
spelling oxford-uuid:58708ec8-8550-406c-bc1b-2be571bb3a1c2022-03-26T17:03:20ZEndocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:58708ec8-8550-406c-bc1b-2be571bb3a1cEnglishSymplectic Elements at Oxford2003Meston, NDavies, RMullins, RJenkinson, CWass, JStradling, JROBJECTIVE: Obstructive sleep apnoea (OSA) is a relatively common condition producing disabling somnolence and profound physiological responses to hypoxaemic episodes during sleep, including significant oscillations in blood pressure. This study aimed to provide controlled data on the interaction between OSA and endocrine axes to establish whether overrepresentation of pathology such as hypertension and hypogonadism in OSA subjects might have an endocrine basis. DESIGN, SETTING AND SUBJECTS: Parallel randomized sham placebo controlled 1-month trial of nasal continuous positive airway pressure (nCPAP) in 101 male subjects with OSA presenting to a respiratory sleep clinic. METHODS: Analysis of gonadotrophins, testosterone, sex hormone binding protein (SHBG), prolactin, cortisol, thyroid stimulating hormone (TSH), free thyroxine (free T4), insulin-like growth factor-1 (IGF-1), renin and aldosterone were performed at baseline and after 1 month's active or placebo nCPAP intervention. Quality of life questionnaire scoring was also recorded over the same time period. RESULTS: Testosterone and SHBG showed significant negative correlations with baseline OSA severity. Active treatment of OSA produced SHBG elevation and TSH reduction (P< or =0.03). Both groups showed an increase in aldosterone (P<0.001) and IGF-1 (P< or =0.03), associated with a large improvement in subjective quality of life scoring. CONCLUSIONS: These findings demonstrate significant changes in endocrine axes not previously reported in a placebo-controlled trial. OSA is a recognized reversible cause of testosterone reduction; SHBG suppression correlating to baseline OSA severity supports a diagnosis of secondary hypogonadism. Significant rises in aldosterone and IGF-1 on treatment coincide with increased physical activity and an improved quality of life score.
spellingShingle Meston, N
Davies, R
Mullins, R
Jenkinson, C
Wass, J
Stradling, JR
Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea.
title Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea.
title_full Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea.
title_fullStr Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea.
title_full_unstemmed Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea.
title_short Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea.
title_sort endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea
work_keys_str_mv AT mestonn endocrineeffectsofnasalcontinuouspositiveairwaypressureinmalepatientswithobstructivesleepapnoea
AT daviesr endocrineeffectsofnasalcontinuouspositiveairwaypressureinmalepatientswithobstructivesleepapnoea
AT mullinsr endocrineeffectsofnasalcontinuouspositiveairwaypressureinmalepatientswithobstructivesleepapnoea
AT jenkinsonc endocrineeffectsofnasalcontinuouspositiveairwaypressureinmalepatientswithobstructivesleepapnoea
AT wassj endocrineeffectsofnasalcontinuouspositiveairwaypressureinmalepatientswithobstructivesleepapnoea
AT stradlingjr endocrineeffectsofnasalcontinuouspositiveairwaypressureinmalepatientswithobstructivesleepapnoea